^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RP12146

    i
    Other names: RP12146, RP 12146, RP-12146
    Associations

    News

    Trials
    Company:
    Rhizen
    Drug class:
    PARP1 inhibitor, PARP2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=23, Completed, Rhizen Pharmaceuticals SA | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    HRD (Homologous Recombination Deficiency)
    |
    RP12146
    8ms
    Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Rhizen Pharmaceuticals SA | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial primary completion date • Metastases
    |
    HRD (Homologous Recombination Deficiency)
    |
    RP12146
    over1year
    Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a PARP Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Rhizen Pharmaceuticals SA | Recruiting --> Active, not recruiting | N=60 --> 23 | Trial completion date: Aug 2023 --> Feb 2024 | Trial primary completion date: May 2023 --> Dec 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    HRD (Homologous Recombination Deficiency)
    |
    RP12146
    over2years
    Activity of RP12146, a novel, selective, and potent small molecule inhibitor of PARP 1/2, in solid tumors (AACR 2022)
    Combination of RP12146 with Temozolomide, Topotecan, Lurbinectedin, and Abemaciclib demonstrated either additive or synergistic effects manifested by an inhibition in growth of solid tumor cell lines. Data demonstrate the therapeutic potential of RP12146 as single agent and in combination in solid tumors. RP12146 is currently being evaluated in Phase 1 clinical trials in patients with locally advanced or metastatic solid tumors (NCT05002868).
    BRCA Biomarker • PARP Biomarker
    |
    BRCA (Breast cancer early onset) • PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    BRCA mutation
    |
    cisplatin • temozolomide • Verzenio (abemaciclib) • topotecan • Zepzelca (lurbinectedin) • RP12146
    3years
    Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a PARP Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Rhizen Pharmaceuticals SA | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    HRD (Homologous Recombination Deficiency)
    |
    RP12146
    over3years
    Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a PARP Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Rhizen Pharmaceuticals SA
    Clinical • New P1 trial
    |
    HRD (Homologous Recombination Deficiency)
    |
    RP12146